Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

S. E. Inzucchi, Richard M. Bergenstal, John B. Buse et al. · Diabetologia · 2012 · 3.9K citations · Full text

Medicine, Endocrinology, Internal Medicine +13

Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes Mellitus<SUBTITLE>Progressive Requirement for Multiple Therapies (UKPDS 49)</SUBTITLE>

Robert C. Turner · JAMA · 1999 · 2.4K citations

Medicine, Endocrinology, Pharmacotherapy +12

Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379

SE Inzucchi, RM Bergenstal, M. Diamant et al. · Diabetes Care · 2013 · 807 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors

Rolf Grempler, Leo Thomas, Matthias Eckhardt et al. · Diabetes Obesity and Metabolism · 2011 · 603 citations

Medicine, Pharmacokinetics, Pharmacology +17

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Hans‐Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker et al. · Diabetes Care · 2014 · 393 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16